Thanks for the comments. I'll read this weekend. I am more curious on if there is something in the package which will have negative implications on their Oral drug.
I do remember Cardiome management remarking about why a panel was requested and they said they believed it was more related to the other drug and to contrast.
Market Data 
Markets 
AI
